Details of the Drug Formulation (DFM)
General Information of DFM (ID: F23666) | |||||
---|---|---|---|---|---|
Name |
Carboplatin 50mg/5ml injectable
|
||||
Company |
Auromedics Pharma
|
||||
Active Pharmaceutical Ingredient (API) | Carboplatin | API Info click to show the detail info of this API | |||
Approved | |||||
Drug Inactive Ingredient (DIGs) | |||||
DIG ID | DIG Info | DIG Name | DIG Functional Class | ||
E0Q6DQ | DIG Info | Mannitol | Diluent ... | ||
E0H2SC | DIG Info | Water | Solvent | ||
Full List of Biological Targets of DIG (DBTs) Regulated by DIG(s) in This DFM | ||||||
---|---|---|---|---|---|---|
Transmembrane channel/porin (TC/P) | ||||||
DBT Name: Glycine receptor alpha-1 (GLRA1) | Click to Show/Hide | |||||
Detailed Information | DBT Info click to show the detail info of this DBT | |||||
Experiment for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
Interacting DIG | Mannitol | |||||
Biological Activity | EC50 = 12589.25 nM (estimated based on the structural similarity with CHEMBL604608 ) | [1] | ||||
Structural Similarity | Tanimoto coefficient = 0.804878049 | |||||
Tested Species | Homo sapiens (Human) | |||||
UniProt ID | GLRA1_HUMAN | |||||
References | |||||
---|---|---|---|---|---|
1 | Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett. 2017 Jun 1; 27(11):2239-2258. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.